Form 4: GE HealthCare CEO AVS Receives Equity Award

Philip Rackliffe, CEO of AVS at GE HealthCare Technologies Inc., was granted 9,356 restricted stock units and 24,598 employee stock options.

Summary

• Philip Rackliffe, CEO, AVS of GE HealthCare Technologies Inc. (GEHC), was awarded equity compensation.
• The award includes 9,356 restricted stock units (RSUs) and 24,598 employee stock options.
• The transaction date for these awards was March 2, 2026.
• Each RSU represents the right to receive one share of GE HealthCare common stock upon settlement.
• The RSUs will vest in three tranches: 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029.
• The employee stock options have an exercise price of $80.16 per share.
• The options will become exercisable in three tranches: 33% on September 2, 2027, 33% on September 2, 2028, and 34% on September 2, 2029.
• The employee stock options expire on March 2, 2036.
• Following these transactions, Philip Rackliffe beneficially owns 26,729 shares of common stock and 24,598 employee stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it reinforces executive alignment with long-term shareholder interests through standard equity compensation practices.

Positives

• The equity awards align the interests of CEO, AVS Philip Rackliffe with those of GE HealthCare Technologies Inc. shareholders.
• The multi-year vesting schedule for both restricted stock units and stock options encourages long-term commitment and performance from the executive.

Future Outlook

The multi-year vesting schedule for the equity awards indicates a long-term incentive structure designed to retain the executive and align their performance with the company's future growth and shareholder value creation through at least September 2029.

Industry Context

StockSavvy.ai notes that the granting of restricted stock units and employee stock options is a standard practice in executive compensation across the healthcare technology industry. This approach is widely used to incentivize leadership, promote long-term strategic alignment, and retain key talent in a competitive market.

Comparison to Industry Standards

• The use of a combination of restricted stock units (RSUs) and stock options is a common structure for executive long-term incentive plans, comparable to practices at peer companies like Siemens Healthineers AG and Medtronic plc, which also utilize performance-based equity awards to align executive interests with shareholder returns.
• The three-year vesting schedule (33%, 33%, 34%) is typical for executive equity grants, providing a sustained incentive period similar to what is observed at major medical device and healthcare IT firms such as Abbott Laboratories and Danaher Corporation.
• The exercise price of $80.16 for the stock options, presumably at or above the market price on the grant date, is standard for incentive stock options, ensuring that the executive benefits only if the company's stock price appreciates.

Stakeholder Impact

• Shareholders: The equity awards are designed to align the executive's financial incentives with shareholder value creation over the long term.
• Employees: While not directly impacting all employees, executive compensation practices can influence overall company culture and compensation philosophy.

Next Steps

• First tranche of restricted stock units and employee stock options will vest/become exercisable on September 2, 2027.
• Second tranche of restricted stock units and employee stock options will vest/become exercisable on September 2, 2028.
• Third tranche of restricted stock units and employee stock options will vest/become exercisable on September 2, 2029.
• Employee stock options will expire on March 2, 2036.

Key Dates

Keywords

GE HealthCare Technologies, GEHC, Form 4, Insider Transaction, Equity Compensation, Restricted Stock Units, Stock Options, Executive Compensation, Philip Rackliffe